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Objective: Reliable and valid needs assessment measures 
are important assessment tools in cancer survivorship care. 
A new 30‑item short‑form version of the Survivor Unmet 
Needs Survey (SF‑SUNS) was developed and validated with 
cancer survivors, including hematology cancer survivors; 
however, test–retest reliability has not been established. The 
objective of this study was to assess the test–retest reliability 
of the SF‑SUNS with a cohort of lymphoma survivors (n = 40). 
Methods: Test–retest reliability of the SF‑SUNS was conducted 
at two time points: baseline (time 1) and 5 days later 
(time 2). Test–retest data were collected from lymphoma cancer 
survivors (n = 40) in a large tertiary cancer center in Western 
Australia. Intraclass correlation analyses compared data at time 
1 (baseline) and time 2 (5 days later). Cronbach’s alpha analyses 
were performed to assess the internal consistency at both time 
points. Results: The majority (23/30, 77%) of items achieved 
test–retest reliability scores 0.45–0.74 (fair to good). A high 
degree of overall internal consistency was demonstrated 
(time 1 = 0.92, time 2 = 0.95), with scores 0.65–0.94 across 
subscales for both time points. Conclusions: Mixed test–retest 
reliability of the SF‑SUNS was established. Our results indicate 
the SF‑SUNS is responsive to the changing needs of lymphoma 
cancer survivors. Routine use of cancer survivorship specific 
needs‑based assessments is required in oncology care today. 
Nurses are well placed to administer these assessments 
and provide tailored information and resources. Further 
assessment of test–retest reliability in hematology and other 
cancer cohorts is warranted.
Key words: Cancer survivorship, internal consistency, 
lymphoma, short‑form Survivor Unmet Needs Survey, 
test–retest reliability
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Introduction
Lymphoma blood cancers are malignant T or B cell 
lymphocytes in the lymphatic system and are categorized 
under two main types: non‑Hodgkin lymphoma (NHL) and 
Hodgkin Lymphoma (HL). NHL represents approximately 
88% of  all lymphomas, while HL is predominately 
diagnosed in the adolescent and young adult population.[1] 
Combined, they represent the sixth most common cancer 
diagnosis worldwide.[1] Consistent with worldwide trends, 
the incidence of  lymphoma in Australia is increasing, 
and with a projected diagnosis of  6232 cases in 2017, this 
equates to 4.6% of all cancer cases.[2] An estimated mortality 
rate of  1481 equates to 3.1% of  all deaths from cancer in 
2017.[2] Projected figures for 2017 in the USA have a similar 
projected incidence of  lymphoma of  4.8% and mortality 
of  3.6%.[1] Treatment for lymphoma generally comprises 
high‑dose chemotherapy and/or targeted immunotherapy 
agents and may include radiotherapy and hematopoietic 
stem cell transplants.[3] These treatments have resulted in 
an improvement to overall survival of  approximately 76% 
at 5 years compared with 52% at 5 years in the 1980s.[2] 
Notwithstanding the positive impact treatment has had on 
survival rates,[4] the consequences of  disease and treatment 
continue long after treatment completion.[5] Long‑term and 
late effects may produce ongoing unmet needs such as fear 
of  recurrence, fatigue, poor nutrition, exercise, fertility, 
relationship, financial, employment, and insurance issues.[6]
To provide optimal supportive cancer care to lymphoma 
survivors, the identification of  patients’ perceived concerns 
and level of  support needed is required.[5] This is especially 
important	 for	 younger	 patients	 (18–45	 years	 of 	 age)	
where the expectation of  long‑term remission can raise 
additional concerns and unmet needs.[7] Receiving relevant 
information and practical support soon after treatment ends, 
especially resources related to healthy lifestyle behaviors,[7‑11] 
can help mitigate the impact of  disease and treatment and 
lead to fewer unmet needs further along the survivorship 
continuum.[12,13] A qualitative study with lymphoma cancer 
survivors (n = 17) undertaken in Western Australia[14] 
reported unmet informational and practical needs as 
participants transitioned from treatment to the survivorship 
phase. The findings suggested tailored post‑treatment 
support and interventions are fundamental components of  
excellent survivorship care.
The measures used to assess unmet needs are equally 
important. Generic cancer measures which comprise items 
related to diagnosis and treatment are often not specific 
enough for the survivorship phase.[15] Comprehensive, 
relevant, reliable, and validated needs assessment measures 
that are survivor‑specific are essential to capture unmet 
needs that become evident when treatment ends.[15] These 
measures can guide health professionals in providing 
individualized information, support, and resources.[5,15] 
Two recent systematic reviews[15,16] revealed that needs 
assessment tools are varied and may not capture all the 
possible unmet needs patients may have. The reviews 
likewise found validity and reliability evidence limited. 
The Survivor Unmet Needs Survey (SUNS) was identified 
as a measure that had strong psychometric properties 
and was developed and psychometrically tested with a 
large cross‑sectional sample of  cancer survivors (n = 550) 
including a small cohort of  hematology cancer participants 
(n = 31, 5.6%).[17] Campbell et al.[17] confirmed a high 
overall internal consistency of  items for their study with an 
overall Cronbach’s alpha of  0.99. The authors also reported 
high	 test–retest	 reliability	 although	 the	 results	were	not	
published.[17] Internal consistency of  the SUNS was further 
tested in two studies of  hematological cancer survivor 
cohorts. A cross‑sectional study with 529 hematological 
cancer survivors[18] demonstrated overall Cronbach’s 
alpha values >0.9, and a weighted Kappa coefficient 
score	of 	>0.6	 for	 test–retest	 reliability;	acceptability	was	
reported for 40/89 (45%) items. Qualitative data from 17 
semi‑structured interviews indicated that the SUNS was 
considered relevant by this cohort of  hematological cancer 
survivors.[18] A cross‑sectional study of  hematological 
cancer survivors from Australia and Canada (n = 437) 
reported similar levels of  unmet needs across the two 
cohorts using the SUNS, with fatigue (n = 76, 17%) and 
financial concerns (n = 39, 9%) rated as high unmet 
needs.[9] Despite the clinical utility of  the original SUNS, 
it was considered potentially burdensome for use in the 
clinical setting given the large number of  items (n = 89). 
In 2014, the 30‑item short‑form‑SUNS (SF‑SUNS) was 
developed and validated with a mixed sample of  cancer 
survivors (n = 1589), including hematological cancer 
survivors (n = 84, 5%).[5] Construct validity and intraclass 
correlation coefficients (ICCs) of  the SF. were similar to 
those of  the original SUNS. Cronbach’s alpha scores for 
the	final	four	domains	were	≥0.85,	and	ICCs	for	the	three	
domains from the original SUNS (financial concerns, 
information, and access and continuity of  care) and 
the SF‑SUNS were high (>0.9). Discriminant validity 
demonstrated the SF‑SUNS ability to discriminate between 
individuals who had recently received treatment and those 
who had not. The authors recommended further testing 
of 	 the	SF‑SUNS	 for	 test–retest	 reliability.[5] The 30‑item 
SF‑SUNS was therefore judged to be more practical and 
likely to be completed by participants in our larger study, 
particularly as the SF‑SUNS was one of  four instruments 
to be administered to participants in a pilot randomized 
trial to measure the effect of  a nurse‑led survivorship model 
of  care.[19]
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For researchers and clinicians to develop targeted follow‑up 
support for cancer cohorts underrepresented in survivorship 
literature, such as lymphoma,[20] cohort‑specific studies in 
the early survivorship phase are required.[21] Therefore, this 
study recruited only those with a lymphoma diagnosis who 
had completed treatment. Discerning the issues and concerns 
of  this group requires survivor‑specific measures that are 
psychometrically sound and fully tested. The SF‑SUNS has 
been	used	within	the	clinical	setting;	however,	since	test–retest	
reliability of the SF‑SUNS had not been established, the aim 
of	the	present	study	was	to	establish	test–retest	reliability	of 	
the SFSUNS to add to the psychometric data available in the 
published literature on this instrument.
Methods
Design
Test–retest	reliability	of	the	SF‑SUNS	was	conducted	at	
two time points: baseline (time 1) and 5 days later (time 2). 
This time frame was chosen to reduce recall bias and change 
in the level of unmet needs.[22] Ethical approval to conduct the 
study was obtained from the human research ethics committee 
of the study site (2015‑020) and university (015007F).
Population and setting
A convenience sample of  40 lymphoma cancer patients 
who were 3 months’ posttreatment completion were 
recruited from the hematology department of  a large 
tertiary hospital in Western Australia. Inclusion criteria 
were pathologically confirmed new diagnosis of  NHL or 
HL; completed first‑line curative intent chemotherapy or 
second‑line curative intent autologous stem cell transplant 
within the previous 3 months; no radiological evidence 
of  lymphoma posttreatment (on positron emission 
tomography [PET] scan); able to understand and read 
English; and over 18 years of age. Participants were excluded 
if  they had not been treated with chemotherapy; had received 
further treatment at another hospital (as experiences or 
interventions may have introduced bias); or were cognitively 
impaired or experiencing an acute mental health condition 
that prohibited the provision of  informed consent.
Sample size
The sample size calculation was derived from Walter 
et al.[23] and used a fixed alpha of  0.05 from two observations 
with reliability values of  R0 = 0.6 (acceptable) and 
R1 = 0.8 (expected), indicating a minimum sample size 
of  n = 39.
Short‑form Survivor Unmet Needs Survey
The SF‑SUNS assesses unmet needs across four domains: 
information needs (3 items); work and financial needs 
(8 items); access and continuity of  care needs (6 items); and 
coping, sharing, and emotional needs (13 items). Patient 
self‑reported concerns and the level of  support required 
are	measured	using	a	Likert‑type	scale:	0	–	no	unmet	need,	
1	–	low	unmet	need,	2	–	moderate	unmet	need,	3	–	high	
unmet	need,	and	4	–	very	high	unmet	need.	Domain	scores	
are generated by adding each item score and dividing by 
the total number of  domain items.[24]
Procedure
The researcher identified and approached eligible 
participants after treatment completion to discuss the 
study and provide them with a participant information and 
consent form. Following informed consent, demographic 
and baseline (time 1) SF‑SUNS questionnaires were then 
administered to participants. After completion of  the 
questionnaires, participants were provided with another 
blank copy of  the SF‑SUNS accompanied by instructions 
to complete the questionnaire at home 5 days later and 
postback using the supplied reply‑paid addressed envelope. 
Participants were advised to record the date of  completion 
if  this differed from the specified due date.
Data collection
At the request of  the research team’s hematologist, 
baseline demographic and SF‑SUNS data were collected 
from consenting participants 3 months posttreatment 
completion and PET scan to confirm the absence of  
disease. Demographic information obtained included 
lymphoma type, stage of  disease, type of  treatment 
received (chemotherapy +/− radiotherapy), date of  
diagnosis, time since diagnosis, comorbid conditions, 
gender, age, weight, marital status, age of  children (if  any), 
postcode, occupation, income level, education level, and 
health behaviors such as smoking and alcohol consumption. 
Participants then completed the SF‑SUNS at time 2 
(5 days following time 1 completion) at home.
Data analysis
All analyses were performed using IBM SPSS Statistics 
Version 25 data analysis software (IBM Corp. Released 
2017. IBM SPSS Statistics for Macintosh, Version 25.0. 
Armonk, NY: IBM Corp). Descriptive statistics were 
used to analyze all data. Descriptive analyses were used 
to analyze and describe demographic data. To assess for 
absolute	 consistency	 of 	 SF‑SUNS	 items	 for	 test–retest	
reliability data, an ICC with a random‑effects model was 
used to compare each item at time 1 and time 2. The ICC 
measure was chosen for its ability to discriminate between 
sets of  scores ranked in the same order but not necessarily in 
agreement	and	adjusts	for	the	degree	of	test–retest	agreement	
expected by chance.[25,26] The closer the value of  the ICC 
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qualification (n = 16, 40%) [Table 1]. Although the majority 
of  participants were currently working (n = 15, 37.5%) and 
had been throughout their treatment, 30% (n = 12) were 
looking for work or had no return to work date set. Over 
half  the participants had a partner (n = 25, 62.5%). Forty 
participants completed both time 1 and time 2 SF‑SUNS. 
The majority of  participants (n = 35, 87.5%) completed time 
2	SF‑SUNS	5	days	after	time	1	(range	4–7	days).
Test–retest
ICCs, 95% confidence intervals, and clinical significance 
are shown in Table 2. One (3%) item met the “excellent” 
criteria for clinical significance; Finding car parking I can 
afford at the hospital or clinic. Twelve (40%) items met the 
“good”	criteria	(0.60–0.74)	and	11	(37%)	items	met	the	“fair”	
criteria	(0.40–0.59).	In	summary,	test–retest	data	showed	“fair”	
to “good” reliability for the majority of items (23/30, 77%).
Internal consistency
Overall Cronbach’s alphas were 0.92 at time 1 and 
0.94 at time 2, with subscales [Table 2] ranging from 
0.74 and 0.69 for information needs, 0.65 and 0.83 for 
work and financial needs, 0.89 and 0.85 for access and 
continuity of  care, and 0.90 and 0.94 for coping, sharing, 
and emotional needs, respectively. These results support 
strong internal consistency for the overall scale. Item‑to‑total 
correlations between 0.40 and 0.70 indicate that items 
are not redundant or measuring needs similar to other 
items within the instrument.[30] Using this criterion, the 
SF‑SUNS demonstrated item‑to‑total correlations between 
0.40 and 0.70 at time 1 for 24 items (80%) and at time 2 
for 19 items (63%) [Table 2]. The majority of  items were 
considered relevant and to be measuring unique needs.
Discussion
Our	study	 is	 the	 first	 to	report	 test–retest	data	 for	 the	
SF‑SUNS. The majority of  items met absolute consistency 
for	reliability	ICC	scores	of 	>0.40	for	test–retest,	categorized	
as “fair” to “good.” An “excellent” clinical significance 
score was achieved for only one item (3%), related to car 
parking costs which are unlikely to change over time. 
Needs‑based instruments such as the SF‑SUNS measure the 
degree of  an individual’s perceived unmet need at one point 
in time. Importantly, Cronbach’s alpha scores at time 1 and 
time 2 demonstrated a high degree of  internal consistency 
and high item‑to‑total correlations, confirming that items 
in the tool were reliable.
A criterion for psychometrically sound needs‑based tools 
is the requirement for an instrument to be responsive to 
changes over time.[31‑33] Although our ICC results may reflect 
the responsiveness of  the SF‑SUNS to changes in need 
over the data collection period, further research is required 
to 1.0, the greater the reliability of  the item or measure.[27] 
The guidelines developed by Cicchetti and Sparrow[28] were 
used to determine the level of  clinical significance of  
the	ICC	values	obtained:	<0.40	=	poor,	0.40–0.59	=	fair,	
0.60–0.74	=	good,	and	>0.75	=	excellent.	For	 this	study,	
items classified as achieving “fair to excellent” reliability, 
ICC >0.40,[29] were reported. Cronbach’s alpha, a measure of  
internal consistency, was used to measure the scale reliability.
To examine the distribution of  unmet needs, the 
five levels of  unmet need were collapsed to three levels. 
A score of  0 (no unmet need) remained the same. Scores 
of  1 or 2 (low and moderate unmet need) were reclassified 
as	 1	 (low–moderate	unmet	 need),	 and	 scores	 of 	 3	 or	 4	
(high and very high unmet need) were classified as 2 
(high–very	high	unmet	need).
Results
Participant characteristic
There were slightly more male (n = 22, 55%) participants, 
and a greater number of  participants with NHL 
(n = 29, 72.5%) compared with HL (n = 11, 27.5%) [Table 1]. 
This was in keeping with the current disease statistics which 
reflect a greater number of  NHL than HL diagnoses.[1] 
Almost one‑third of  participants were aged between 18 and 
39 years (32.5%), and a greater proportion had a university 
Table 1: Baseline participant demographic and disease 
characteristics (n=40)
Characteristics n (%)
Gender
Male 22 (55.0)
Female 18 (45.0)
Age group (years)
18‑39 13 (32.5)
40‑59 12 (30.0)
60‑74 9 (22.5)
75+ 6 (15.0)
Marital status
Single 10 (25.0)
Married/de facto 25 (62.5)
Divorced 3 (7.5)
Widowed 2 (5.0)
Lymphoma diagnosis
Non‑Hodgkin 29 (72.5)
Hodgkin 11 (27.5)
Highest level of education
Secondary school or less 11 (27.5)
Trade, vocational college 13 (32.5)
University or higher 16 (40.0)
Employment status
Working 15 (37.5)
Retired 13 (32.5)
Looking for work/no return to work date 12 (30.0)
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to detect clinically meaningful change for patients.[16] All 
participants completed the time 2 questionnaire at home, 
well away from the hematology clinic where the time 1 
questionnaire was completed. It is possible that participants 
may have had additional time to more accurately reflect 
on the level of  unmet need. Similarly, time 1 scores may 
have been impacted by participants’ anxiety at the hospital 
appointment where patients often worry about test results 
and potential relapse.[34] In addition, fatigue is a recognized 
effect of  lymphoma treatment[7] and may have potentially 
Table 2: Item test‑retest reliability and internal consistency (n=40)
Domain (n=4) Item description ICC (95% CI) Level of clinical 
significance
Cronbach’s alpha Item‑to‑total 
correlation
Time 1 Time 2 Time 1 Time 2
Information needs Items (n=3) 0.74 0.69
Finding information about complementary or alternative 
therapies
0.69 (0.49‑0.83) Good 0.30 0.50
Dealing with fears about cancer spreading 0.56 (0.30‑0.74) Fair 0.59 0.63
Dealing with worry about whether treatment has 
worked
0.57 (0.32‑0.75) Fair 0.65 0.71
Work and financial 
needs
Items (n=8) 0.65 0.83
Worry about earning money 0.63 (0.40‑0.79) Good 0.49 0.47
Having to take a pension or disability allowance 0.39 (0.09‑0.62) Poor 0.45 0.38
Paying household bills or other payments 0.69 (0.49‑0.83) Good 0.55 0.60
Finding what type of financial assistance is available and 
how to obtain it
0.70 (0.50‑0.83) Good 0.67 0.71
Finding car parking that I can afford at the hospital or 
clinic
0.76 (0.59‑0.86) Excellent 0.02 0.45
Understanding what is covered by my medical insurance 
or benefits
0.31 (0.01‑0.57) Poor 0.20 0.06
Knowing how much time I would need away from work 0.74 (0.55‑0.85) Good 0.55 0.50
Doing work around the house (cooking, cleaning, home 
repairs, etc.)
0.37 (0.07‑0.61) Poor 0.12 0.70
Access and continuity 
of care
Items (n=6) 0.89 0.85
Having access to cancer services close to my home 0.45 (0.16‑0.66) Fair 0.44 0.62
Getting appointments with specialists quickly 
enough (oncologist, surgeon, etc.)
0.38 (0.08‑0.61) Poor 0.70 0.44
Getting test results quickly enough 0.66 (0.44‑0.81) Good 0.57 0.51
Having access to care from other health 
specialists (dietitians, physiotherapists, occupational 
therapists)
0.53 (0.26‑0.72) Fair 0.51 0.67
Making sure I had enough time to ask my doctor or 
nurse questions
0.58 (0.33‑0.75) Fair 0.59 0.48
Getting the health care team to attend promptly to my 
physical needs
0.53 (0.26‑0.72) Fair 0.59 0.50
Coping, sharing and 
emotional needs
Items (n=13) 0.90 0.94
Telling others how I was feeling emotionally 0.43 (0.14‑0.65) Fair 0.58 0.48
Finding someone to talk to who understands and has 
been through a similar experience
0.33 (0.02 to 0.58) Poor 0.45 0.57
Dealing with people who expect me to be “back to 
normal”
0.62 (0.39‑0.78) Good 0.57 0.77
Dealing with people accepting that having cancer has 
changed me as a person
0.51 (0.24‑0.71) Fair 0.68 0.81
Dealing with reduced support from others when 
treatment has ended
0.67 (0.46‑0.81) Good 0.82 0.82
Dealing with feeling depressed 0.73 (0.55‑0.85) Good 0.53 0.72
Dealing with feeling tired 0.49 (0.21‑0.69) Fair 0.57 0.71
Dealing with feeling stressed 0.55 (0.29‑0.74) Fair 0.78 0.69
Dealing with feeling lonely 0.72 (0.52‑0.84) Good 0.53 0.61
Dealing with not being able to feel “normal” 0.47 (0.20‑0.68) Fair 0.57 0.70
Trying to stay positive 0.63 (0.40‑0.79) Good 0.55 0.65
Coping with having a bad memory or lack of focus 0.64 (0.41‑0.79) Good 0.50 0.86
Dealing with changes in how my body appears 0.28 (−0.04‑0.54) Poor 0.23 0.24
ICC: Intraclass correlation, CI: Confidence interval
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affected participant responses at either time point. Finally, 
most items were similarly balanced for both time points 
from “no unmet need” to “low unmet need” or “low unmet 
need” to “no unmet need.”
It is important to allow cancer survivors the opportunity to 
self‑identify unmet needs and issues of concern. Survivorship 
needs‑based instruments provide a consistent method for 
this purpose.[35] Furthermore, it is important that any tool 
is responsive to change as individuals’ issues, concerns, 
thoughts, and feelings can change from day‑to‑day,[32,33] 
particularly during survivorship transition as individuals 
move on with their lives after cancer treatment. Such 
reliable and valid instruments can facilitate individualized 
survivorship care and tailored support and resources.[15]
It is important to note that the original SUNS 
demonstrated	 low	 test–retest	 reliability	 acceptability,[18] 
with	the	authors	suggesting	that	the	test–retest	timeframe	
was too long at 28 days. Since our study was part of  a 
larger study involving an intervention group, a 5‑day 
later	 test–retest	 assessment	was	 deemed	 an	 appropriate	
timeframe to ensure completion of  the time 2 SF‑SUNS 
before the implementation of  any needs‑based interventions 
associated with the larger study.[19] Importantly, this time 
period	was	also	in	keeping	with	the	recommended	2–14‑day	
time	period	for	test–retest	procedures.[31‑33]
A limitation of  this study may have been the sample 
size of  40 participants, despite sample size calculations 
indicating that this number would be sufficient to adequately 
perform	 test–retest	 reliability	with	 confidence.	Many	
participants (n = 16, 40%) attended the baseline appointment, 
where time 1 SF‑SUNS was administered, accompanied by a 
support person (partner or family member). We acknowledge 
that this may have influenced time 1 responses. Likewise, 
time 2 responses may have similarly been influenced as the 
SF‑SUNS was completed at home. We can confirm that 
participants did not receive any needs‑based interventions 
between time 1 and time 2 completion of  the SF‑SUNS.
Conclusion
We suggest that needs‑based assessments should 
be used routinely during the survivorship period to 
facilitate survivorship care that is tailored and responsive 
to individuals’ changing needs. Valid and reliable 
survivor‑specific measures are essential for routine 
screening and follow‑up. Nurses in particular are a 
valuable resource in the survivorship phase to assess for 
areas of  concern or unmet needs and for the provision 
of  information, support, and resources that are tailored 
to the individuals’ unique needs. Further testing of  the 
SF‑SUNS is recommended in hematology and other cancer 
populations to further understand and demonstrate the 
responsiveness of  this instrument to changes in need over 
the survivorship period.
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